RSS Feed
April 28th, 2012 
FAKE NEWS for the Zionist agenda 
Novartis, the pharmaceuticals corporation is suing The National Health Service’s (NHS) state-run hospitals in Britain.
The corporation wants them to use Lucentis, an eye drug that costs 700 pounds, or $1,130 US dollars.
Novartis claims the judicial review is a last resort. It is decrying patient safety being compromised without the use of the expensive drug.
Doctors for the NHS are allowed to use any drug at their discretion. This legal decision could alter that freedom. If a drug corporation can force doctors to use a certain drug simply because the corporation wants them to, then healthcare could effectively be censored by drug corporations. The best treatment for patients is not a point of discussion. This argument is about profits for Novartis.
Independent groups are calling for a review that will determine which drug should be used. Helen Jackman, chief executive for the Macular Disease Society said, “If Avastin is not as safe as Lucentis, no one should be using it. If it is as good, perhaps everyone should be using it.”
The NHS was prescribing the cheaper version called Avastin; a cancer drug made by Novartis’ competitor Genetech, Inc. Avastin has not been officially approved for its use by the hospitals.
The Health Service’s Advisory Board (NICE) make decisions on which drug can be approved for which use. NICE uses analysis of cost effectiveness in their decision process.
After four hospitals in the South of England agreed to pay for Avastin when prescribed by doctors, Novartis filed suit.
In their complaint, Novartis claims they are concerned patients and doctors are being coerced into using Avastin to cut costs for the NHS. By British governmental mandate, the NHS was told to “trim” 20 billion pounds from its 2015 budget.
Novartis remarked, “It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available.”
Then Novartis claimed that Avastin was dangerous with “emerging evidence” that the drug was unsafe for its use by the NHS hospitals.
Alexander Klauser, Roche spokesperson (Roche owns Novartis) said, “No studies have been done for Avastin and (macular degeneration) and this is not the plan.” They have no scientific proof that Avastin is dangerous; they simply are claiming it because the drug is cutting into their profits.
“Companies like Novartis should not be in the position to block moves to more cost-effective treatments in order to maximize their profits,” said John Harris, of the Institute for Science Ethics and Innovation at the University of Manchester, in a statement.
Harris believes it is appropriate for health providers to use treatments that were much cheaper than ones that were already licensed.
Posted in 
Tags: 
